The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

BackgroundPD-1/L1 inhibitor-based immunotherapy is currently under investigation in biliary tract cancer (BTC). Apatinib combined with camrelizumab has achieved promising results in various tumor types. The aim of this study was to assess the safety and efficacy of apatinib plus camrelizumab for adv...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Dongxu Wang, Xu Yang, Junyu Long, Jianzhen Lin, Jinzhu Mao, Fucun Xie, Yunchao Wang, Yanyu Wang, Ziyu Xun, Yi Bai, Xiaobo Yang, Mei Guan, Jie Pan, Samuel Seery, Xinting Sang, Haitao Zhao
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2021-04-01
סדרה:	Frontiers in Oncology
נושאים:	apatinib camrelizumab (SHR-1210) advanced biliary tract cancer combination therapy PD-1/L1 blockade target therapy
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fonc.2021.646979/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!